消息面上，1月8日，翰森制药发布公告，集团创新药阿美乐(甲磺酸阿美替尼片)获中国国家药品监督管 理局("NMPA")签发的药品注册证书，批准增加"阿美乐联合培美曲塞和铂类化疗药物适用于具有表皮生 长因子受体("EGFR")外显子19缺失或外显子21(L858R)置换突变的局部晚期或转移性非小细胞肺癌 ("NSCLC")成人患者的一线治疗"适应症。此为阿美乐获批的第五项适应症。 值得一提的是，据翰森制药官微消息，近日，国际顶级肿瘤学期刊《Lancet Oncology》(中文译名： 《柳叶刀.肿瘤学》，影响因子：35.9)在线重磅发布了翰森制药创新药阿美乐(甲磺酸阿美替尼片， 110mg)用于EGFR突变非小细胞肺癌辅助治疗的最新研究结果。数据显示，阿美乐能够显著改善完全切 除的Ⅱ-ⅢB期EGFR突变NSCLC患者的无病生存期(DFS)，且安全性良好。 翰森制药(03692)午前涨超4%，截至发稿，涨3.64%，报42.12港元，成交额9762.23万港元。 ...

Core Viewpoint - Hansoh Pharmaceutical (03692) has seen a stock price increase of over 4%, currently trading at HKD 42.12, following the announcement of a new indication for its innovative drug, Amelot (Ametinib Mesylate Tablets) [1] Group 1: Regulatory Approval - On January 8, Hansoh Pharmaceutical announced that the National Medical Products Administration (NMPA) of China has issued a drug registration certificate for Amelot, approving it for use in combination with pemetrexed and platinum-based chemotherapy for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations [1] - This marks the fifth indication approved for Amelot [1] Group 2: Research Findings - Recent research results published in the prestigious oncology journal, Lancet Oncology, indicate that Amelot significantly improves disease-free survival (DFS) in patients with completely resected stage II-III B EGFR-mutant NSCLC, with good safety profiles [1]

Core Viewpoint - Hansoh Pharmaceutical (03692) has seen a stock price increase of over 4%, currently trading at HKD 42.12, following the announcement of a new indication for its innovative drug Amelot (Ametinib Mesylate Tablets) [1] Group 1: Drug Approval and Indications - On January 8, Hansoh Pharmaceutical announced that its innovative drug Amelot received a drug registration certificate from the National Medical Products Administration (NMPA) in China, approving it for use in combination with pemetrexed and platinum-based chemotherapy for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations [1] - This marks the fifth approved indication for Amelot, highlighting the drug's expanding therapeutic applications [1] Group 2: Research Findings - Recent research results published in the prestigious oncology journal Lancet Oncology indicate that Amelot significantly improves disease-free survival (DFS) in patients with completely resected stage II-III B EGFR-mutant NSCLC, demonstrating good safety [1]

个股消息面上，药明康德发布2025年度业绩预告，预计归属于上市公司股东的净利润为191.51亿元，同 比增长约103%，其中包含了出售联营公司部分股权以及剥离部分业务所获得的投资收益；本期基本每 股收益预计约人民币6.70元/股，同比增长约104.27%。 个股消息面上，药明康德发布2025年度业绩预告，预计归属于上市公司股东的净利润为191.51亿元，同 比增长约103%，其中包含了出售联营公司部分股权以及剥离部分业务所获得的投资收益；本期基本每 股收益预计约人民币6.70元/股，同比增长约104.27%。 责任编辑：郝欣煜 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 1月13日消息，港股创新药概念盘初拉升，药明康德涨超9%，博安生物、三生制药涨超8%，药明生 物、乐普生物涨超6%，复星医药、药明合联、翰森制药涨超4%。 1月13日消息，港股创新药概念盘初拉升，药明康德涨超9%，博安生物、三生制药涨超8%，药明生 物、乐普生物涨超6%，复星医药、药明合联、翰森制药涨超4%。 责任编辑：郝欣煜 热点栏目 自选股 数据中心 行情中心 资金流向 模拟交易 客户端 ...

Macro and Strategy Research - The US manufacturing PMI has further declined in December 2025, marking the largest month-on-month drop since 2024, indicating a prolonged downturn for 10 months, while the service sector PMI remains strong, highlighting structural divergence in the US economy [2][3] - In China, the manufacturing PMI returned above the threshold in December 2025, with improvements in both supply and demand, while the non-manufacturing sector also showed unexpected recovery [3] Fixed Income Research - In December 2025, the central bank's liquidity net injection exceeded 800 billion, with money market rates remaining low, while the yield on 10Y government bonds rose by 1 basis point to 1.85% by the end of December [7][9] - The bond market is expected to maintain a range-bound pattern, with inflation and monetary policy acting as anchors for the upper and lower bounds of this range [9] Industry Research - The listing of Rebio Biotech on the Hong Kong Stock Exchange has increased attention on the small nucleic acid sector, with significant developments in the industry including the approval of new drugs and strategic partnerships [10][12][13] - The SW pharmaceutical index rose by 6.13% in the week of January 5-8, 2026, with all sub-sectors experiencing gains, indicating a strong market performance [13]

Market Overview - The Hong Kong stock market indices collectively rose, with the Hang Seng Index increasing by 1.44% to close at 26,608.48 points, and a total trading volume of HKD 306.23 billion [1] - The Hang Seng Tech Index saw a significant rise of 3.1%, closing at 5,863.2 points, indicating a strong performance in the technology sector [1] Blue-Chip Stocks Performance - Meituan-W (03690) surged by 6.6% to HKD 105, contributing 57.12 points to the Hang Seng Index, with a trading volume of HKD 11.31 billion [2] - Alibaba Health (00241) rose by 10.23% to HKD 6.36, contributing 6.17 points to the index [2] - Kuaishou-W (01024) increased by 7.43% to HKD 80.25, contributing 26.89 points [2] - Other notable movements included a decline in Shenzhou International (02313) by 2.8% and Hansoh Pharmaceutical (03692) by 2.31%, which negatively impacted the index [2] Sector Highlights - The AI sector experienced a significant surge, with stocks like Maifushi (02556) rising by 32.09% and Zhipu (02513) by 31.4%, reflecting a growing interest in AI applications [3][4] - The commercial aerospace sector also saw gains, with Asia Pacific Satellite (01045) increasing by 18.16% and China Technology Group (01725) by 16.84% [5] - Gold stocks were active, with the price of gold surpassing USD 4,600, leading to increases in companies like China Silver Group (00815) and Lingbao Gold (03330) [5][6] Lithium Battery Sector - Lithium battery stocks showed mixed performance, with Ganfeng Lithium (01772) rising by 4.69% while CATL (03750) fell by 2.45% [6] - The recent adjustment in export tax policies for battery products is expected to impact the sector, with potential short-term benefits due to increased export orders before the tax changes take effect [7] Notable Stock Movements - Haowei Group (00501) debuted with a significant increase of 16.22%, closing at HKD 121.8, following its IPO pricing at HKD 104.8 [8] - Baiaosaitu-B (02315) reached a new high, rising by 10.03% to HKD 39.5, following a licensing agreement aimed at accelerating the development of bispecific antibody drug conjugates [9] - COSCO Shipping Energy (01138) continued to rise, up by 9.03% to HKD 11.47, driven by increased shipping demand in the Middle East [10]

Investment Rating - The report maintains a positive outlook on innovative drugs and the related industry chain, indicating potential value revaluation for specific pharmaceutical companies [6][28]. Core Insights - The pharmaceutical sector in A-shares showed strong performance in the second week of January 2026, with the SW Pharma Bio index rising by 7.8%, outperforming the overall market [8][29]. - Key sub-sectors such as medical services (+12.3%), medical equipment (+9.4%), and chemical preparations (+7.3%) demonstrated significant growth during this period [13][29]. - Notable individual stock performances included Innovative Medical Management (+61.0%), Sanbo Hospital Management Group (+56.2%), and MeHow Medical (+56.1%) [15][29]. - The report highlights a normal premium level of 68.3% for the pharmaceutical sector relative to all A-shares as of January 9, 2026 [15][23]. Summary by Sections 1. Continued Focus on Innovative Drugs and Industry Chain - The report emphasizes the high prosperity in innovative drugs and suggests monitoring companies like Jiangsu Heng Rui Medicine, Hansoh Pharmaceutical, 3SBio, Sichuan Kelun Pharmaceutical, and Jiangsu Nhwa Pharmaceutical for potential value revaluation [6][28]. 2. Performance of A-Shares Pharmaceutical Sector - In the second week of January 2026, the A-share pharmaceutical sector outperformed the market, with the SW Pharma Bio index increasing by 7.8% [8][29]. - The report ranks the pharmaceutical sector as the 5th best-performing industry among Shenwan's primary industries during this period [11][29]. 3. Performance of Hong Kong and U.S. Pharmaceutical Sectors - The Hong Kong pharmaceutical sector outperformed the market, with the Hang Seng Healthcare index rising by 10.3% and the biotechnology sector increasing by 11.1% [20][29]. - Conversely, the U.S. pharmaceutical sector underperformed, with the S&P Healthcare Select Sector rising by only 1.1% compared to the S&P 500's 1.6% increase [20][29].

Investment Rating - The report maintains a "Positive" investment rating for the pharmaceutical industry [4] Core Insights - The pharmaceutical index rose by 7.81% from January 5 to January 9, outperforming the CSI 300 index by 5.03%. The brain-machine interface and AI medical sectors are expected to remain active in Q1 2026, with a strong rebound in innovative drugs, particularly small nucleic acids [5][25] - The report highlights the potential for significant advancements in small nucleic acids in 2026, driven by breakthroughs in liver-targeted delivery technologies and a surge in clinical data readouts [8][22] - The report emphasizes the importance of selecting innovative drug stocks with strong fundamentals and suggests focusing on companies that have undergone sufficient adjustments [5][49] Summary by Sections Industry Performance - The pharmaceutical index saw 443 stocks rise and 25 fall during the week, with notable gainers including Innovative Medical (+61.04%) and Sanbo Brain Science (+56.15%). Conversely, Baohua Pharmaceutical saw a decline of -21.65% [5][26][27] Small Nucleic Acids - 2026 is projected to be a pivotal year for the small nucleic acid sector, with advancements in liver-targeted delivery technologies and a high frequency of clinical data readouts expected [8][22] - Arrowhead's delivery platform has shown promising results in clinical trials, validating the feasibility of RNAi therapies for obesity and other conditions [9][11] Investment Recommendations - The report suggests focusing on companies with leading platform capabilities and differentiated pipeline layouts, such as Rebio Biotech, Yuyuan Pharmaceutical, and Frontier Biotech [20][24] - It also recommends a diversified investment approach, including innovative drugs, brain-machine interfaces, and AI medical technologies [47][48] Market Trends - The report notes that the aging population and increasing healthcare demands are driving growth in the pharmaceutical sector, with a focus on chronic diseases and innovative medical technologies [47] - The report highlights the ongoing trend of domestic companies enhancing their capabilities in the global market, particularly in innovative drug development and medical devices [46][47] Key Companies to Watch - Recommended stocks include China National Pharmaceutical Group, Rebio Biotech, Shanghai Yizhong, and Yuyuan Medical [49]

Group 1 - The core point of the news is that Hansoh Pharmaceutical announced the approval of a fifth indication for Amelot (Ametinib Mesylate Tablets) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with specific EGFR mutations [1] - The approval is based on the AENEAS2 Phase III clinical study, which demonstrated that Amelot combined with chemotherapy significantly extends progression-free survival (PFS) compared to monotherapy, with a hazard ratio (HR) of 0.47, indicating a 53% reduction in the risk of disease progression or death [1] - The median PFS was extended to 28.9 months, with an objective response rate (ORR) of 93.2%, and no new safety risks were identified in the study, which included only Chinese patients [1] Group 2 - Since its initial approval in March 2020, Amelot has expanded from a single indication to five, with all previous indications included in the national medical insurance catalog, enhancing its clinical position and providing high-level evidence for the treatment of lung cancer in China [2] - The previously approved indications include postoperative adjuvant therapy for EGFR-mutant NSCLC, maintenance therapy after chemoradiotherapy for unresectable locally advanced NSCLC, and first-line and second-line treatments for advanced NSCLC [2]

Group 1: Acquisition and Strategic Moves - Eli Lilly announced the acquisition of Ventyx Biosciences for $1.2 billion, with a premium of 62%, to enhance its NLRP3 inhibitor pipeline, expected to complete in the first half of 2026 [1] - Bangyao Biotech appointed Xiang Yu as CEO starting January 1, 2026, who brings 17 years of experience in the pharmaceutical and healthcare sectors, aiming to accelerate the commercialization of CGT pipelines [2] Group 2: Market Performance and Product Approvals - Jingfeng Medical's stock surged over 30% on its first day of trading in Hong Kong, reflecting strong market confidence in its surgical robot technology and global strategy [3] - Luye Pharma's innovative drug Ruoxinlin received acceptance for a new indication application in China, targeting generalized anxiety disorder, with a clinical efficacy rate exceeding 80% [4] - Hansoh Pharmaceutical's Amivantamab was approved for a new indication in combination with chemotherapy for advanced non-small cell lung cancer patients with specific EGFR mutations, reinforcing its position in the EGFR-TKI market [5]